Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 CAR-T cells in relapsed/refractory T-cell malignancies
NCT04823091Phase 1Unknown
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Gene Editing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR7-T in T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and T-cell non-Hodgkin lymphoma. Primary endpoint: Incidence of Treatment-related Adverse Events at 2 years. Status: unknown.
02
Drugs
CAR7-T
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04823091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823091.